Development of novel stem cell-based therapies for the treatment of advanced peripheral arterial disease

The purpose of the Project is to develop novel cell therapies to delay the need of amputation and improve the quality of life of patients with advanced PAD, with the overall objective of reduce the incidence of amputation in Peripheral Arterial Disease (PAD). Reference is made to the application dated 7 November 2007 and any subsequent correspondence with the Focal Point. The completed Project shall include the following activities and results: - Project management, - Project preparation, (analysis of the efficacy of HSC-derived endothelial cells in previously administered therapies and prove the safe use of stem cells in therapy), - Laboratory research work for identifying the most suitable isolation methods and cell types with angiogenic potential for clinical trials and the characterisation of these cell types, - Pre-clinical studies (design and development of a clinical protocol to study the efficacy of therapies by CD34 and hemopoetic stem cells and/or mesenchymal stem cells), and - Publicity and dissemination of results. The Project Promoter is the University of Debrecen Medical and Health Science Centre. Subject to national law, the Project shall be implemented in partnership with the Cell Therapy group at the Rikshospitalet, Oslo (Norway). The Focal Point shall ensure that the Project Promoter provides at least 15 percent of the estimated eligible Project cost.